Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging

Belantamab mafodotin (belamaf) is a novel antibody–drug conjugate developed for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Although the drug has demonstrated a good efficacy, corneal adverse events have been reported. In this prospective study, consecutive patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Mencucci, Rita, Cennamo, Michela, Alonzo, Ludovica, Senni, Carlotta, Vagge, Aldo, Ferro Desideri, Lorenzo, Scorcia, Vincenzo, Giannaccare, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147189/
https://www.ncbi.nlm.nih.gov/pubmed/35629012
http://dx.doi.org/10.3390/jcm11102884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147189/
https://www.ncbi.nlm.nih.gov/pubmed/35629012
http://dx.doi.org/10.3390/jcm11102884

Ejemplares similares